Guided treatments via molecular characterization of solid tumors using biomarkers such as immunohistochemistry (IHC) and genomic sequencing has resulted in better outcomes in subsets of patients, such as those with EGFR (epidermal growth factor receptor) mutant lung cancer and BRAF mutant melanoma [5]. Here, BRAF is linked to melanoma.